Executive Summary from the 2023 Charleston HFpEF Conference
- PMID: 39494411
- PMCID: PMC11526490
- DOI: 10.15420/usc.2024.04
Executive Summary from the 2023 Charleston HFpEF Conference
Keywords: AF; HFpEF; exercise training; obesity; outcomes; personalized medicine.
Conflict of interest statement
Disclosure: SEL has received consulting fees from Axon, Corvia, and Eli Lilly and honoraria from Dignity Health and Medscape; and is on an advisory board for Novo Nordisk. RJT has received consulting fees from Abbott, Acorai, Aria CV, Acceleron/Merck, Alleviant, Boston Scientific, Cytokinetics, Edwards Lifesciences, Endotronix, Gradient, Medtronic, Morphic Therapeutic, Restore Medical, and United Therapeutics Corporation; is on an advisory board for Restore Medical; and has stock options in Aria CV. CCFA has no conflicts of interest to declare.
Figures
Publication types
LinkOut - more resources
Full Text Sources